Trials / Completed
CompletedNCT04343092
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- University of Baghdad · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)
Detailed description
Comparing effectiveness of single dose 0.2mg/kg Ivermectin (IVM) plus hydroxychloroquine (HCQ) 400mg BID in first day then 200mg BID for 5 days plus azithromycin (AZT) 500mg in first day then 250mg for 5 days. The comparison group was a historical control population and data collected from the current study were compared to that historical control population
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivermectin (IVM) | Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly |
Timeline
- Start date
- 2020-04-18
- Primary completion
- 2020-05-31
- Completion
- 2020-06-01
- First posted
- 2020-04-13
- Last updated
- 2020-11-04
- Results posted
- 2020-11-04
Locations
1 site across 1 country: Iraq
Source: ClinicalTrials.gov record NCT04343092. Inclusion in this directory is not an endorsement.